Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Tables)

v3.8.0.1
Non-Controlling Interests (Tables)
9 Months Ended
Sep. 30, 2017
Noncontrolling Interest [Abstract]  
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net
Non-controlling interests in consolidated entities, as recorded on the Condensed Consolidated Balance Sheets are as follows:
 
 
 
As of September 30, 2017
 
($ in thousands)
 
Avenue
 
Coronado SO
 
Mustang
 
Checkpoint
 
JMC
 
Helocyte
 
Cellvation
 
Caelum
 
Aevitas
 
National
 
Total
 
NCI equity share
 
$
17,306
 
$
(236)
 
$
47,840
 
$
22,368
 
$
(535)
 
$
(1,848)
 
$
(239)
 
$
7
 
$
(9)
 
$
17,022
 
$
101,676
 
Net loss attributed to non-controlling interests
 
 
(1,329)
 
 
(22)
 
 
(8,268)
 
 
(10,144)
 
 
(150)
 
 
(975)
 
 
(60)
 
 
(1,086)
 
 
(166)
 
 
4,845
 
 
(17,355)
 
Non-controlling interests in consolidated entities
 
$
15,977
 
$
(258)
 
$
39,572
 
$
12,224
 
$
(685)
 
$
(2,823)
 
$
(299)
 
$
(1,079)
 
$
(175)
 
$
21,867
 
$
84,321
 
 
 
 
As of December 31, 2016
 
($ in thousands)
 
Avenue
 
Coronado SO
 
Mustang
 
Checkpoint
 
JMC
 
Helocyte
 
Cellvation
 
National
 
Total
 
NCI equity share
 
$
(494)
 
$
(217)
 
$
12,376
 
$
32,160
 
$
(192)
 
$
(612)
 
$
4
 
$
17,643
 
$
60,668
 
Net loss attributed to non-controlling interests
 
 
(349)
 
 
(19)
 
 
(1,805)
 
 
(11,733)
 
 
(355)
 
 
(1,155)
 
 
(158)
 
 
(621)
 
 
(16,195)
 
Non-controlling interests in consolidated entities
 
$
(843)
 
$
(236)
 
$
10,571
 
$
20,427
 
$
(547)
 
$
(1,767)
 
$
(154)
 
$
17,022
 
$
44,473
 
Components Of Non-Controlling Interests In Loss Of Consolidated Entities
The components of non-controlling interests in loss of consolidated entities, as recorded on the Condensed Consolidated Statement of Operations are as follows:
 
 
 
For the three months ended September 30, 2017
 
($ in thousands)
 
Avenue (2)
 
Coronado
SO
 
Mustang (2)
 
Checkpoint
(1)
 
JMC
 
Helocyte
 
Cellvation
 
Caelum
 
Aevitas
 
National
 
Total
 
Non-controlling interests in loss of consolidated entities
 
$
(1,015)
 
$
(15)
 
$
(3,241)
 
$
(3,437)
 
$
(103)
 
$
(376)
 
$
24
 
$
(835)
 
$
(166)
 
$
(27)
 
$
(9,191)
 
Non-controlling ownership
 
 
66.1
%
 
13.0
%
 
60.8
%
 
61.9
%
 
6.9
%
 
20.0
%
 
22.0
%
 
25.2
%
 
25.3
%
 
43.4
%
 
 
 
 
 
 
For the nine months ended September 30, 2017
 
($ in thousands)
 
Avenue
 
Coronado
SO
 
Mustang
 
Checkpoint
(1)
 
JMC
 
Helocyte
 
Cellvation
 
Caelum
 
Aevitas
 
National
 
Total
 
Non-controlling interests in loss of consolidated entities
 
$
(1,329)
 
$
(22)
 
$
(8,268)
 
$
(10,144)
 
$
(150)
 
$
(975)
 
$
(60)
 
$
(1,086)
 
$
(166)
 
$
4,845
 
$
(16,011)
 
Non-controlling ownership
 
 
28.9
%
 
13.0
%
 
58.7
%
 
61.9
%
 
6.9
%
 
20.0
%
 
22.0
%
 
25.2
%
 
25.3
%
 
43.4
%
 
 
 
 
 
 
For the three months ended September 30, 2016
 
($ in thousands)
 
Avenue
 
Coronado SO
 
Mustang
 
Checkpoint
 
 
JMC
 
Helocyte
 
Total
 
Non-controlling interests in loss of consolidated entities
 
$
(47)
 
$
(4)
 
$
(204)
 
$
(3,254)
 
 
$
(104)
 
$
(362)
 
$
(3,975)
 
Non-controlling ownership (3)
 
 
10.5
%
 
13.0
%
 
23.9
%
 
62.7
%
 
 
8.1
%
 
20.6
%
 
 
 
 
 
 
For the nine months ended September 30, 2016
 
($ in thousands)
 
Avenue
 
Coronado SO
 
Mustang
 
Checkpoint
 
JMC
 
Helocyte
 
Total
 
Non-controlling interests in loss of consolidated entities
 
$
(231)
 
$
(14)
 
$
(363)
 
$
(10,767)
 
$
(333)
 
$
(616)
 
$
(12,324)
 
Non-controlling ownership (3)
 
 
10.5
%
 
13.0
%
 
10.0
%
 
63.5
%(1)
 
8.1
%
 
20.6
%
 
 
 
 
(1)
- Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.
 
 
(2)
- Mustang and Avenue are consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s and Avenue’s Class A preferred shares which provide super-majority voting rights.
 
 
(3)
- Represents a weighted average of ownership during the periods presented.